Perioperative Mortality and Complications in Patients with COVID-19 Undergoing Surgery: A Meta-Regression and Meta-Analysis of 8 Cohort Studies

2020 ◽  
Author(s):  
Hai ping Ma ◽  
Hai Guo ◽  
Long Yang ◽  
Jian rong Ye ◽  
Chun ling Chen ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Meta Analysis ◽  
Perioperative Mortality ◽  
Meta Regression

scholarly journals 2513. The Effect of Treatment Supporter Interventions on ART Adherence in Eastern and Southern Africa: a systematic review and meta-analysis

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S872-S873
Author(s):  
Ya Haddy Sallah ◽  
Thabani Nyoni ◽  
Kim Lipsey
Keyword(s):  
Cohort Studies ◽  
Southern Africa ◽  
Meta Analysis ◽  
Standard Of Care ◽  
Cochrane Library ◽  
Virologic Suppression ◽  
Art Adherence ◽  
Meta Regression ◽  
Eastern And Southern Africa ◽  
Study Type

Abstract Background Access to ART has significantly reduced morbidity and mortality and improved quality of life in people living with HIV (PLWH). Treatment supporter interventions (TSIs) utilize patient or facility selected individuals to increase optimal ART adherence through home visits, peer support and medication management. This aim of this meta-analysis is to evaluate the effectiveness of TSIs in improving optimal ART adherence among PLWH in SSA using process- and outcome-oriented measures. Methods We searched PubMed, EMBASE, SCOPUS, Web of Science (WOS), Cochrane Library, and ClinicalTrials.gov for randomized controlled trials or cohort studies comparing treatment supporter interventions to the standard of care conducted in Eastern and Southern Africa. The primary outcomes were ART adherence measured by pill counts and virologic suppression. Pooled risk ratios with 95% confidence intervals were calculated using random-effects models. Stratified analyses and meta-regression were conducted to determine the effect of study type and patient nomination of treatment supporters on ART adherence. Results Sixteen studies, 10 RCTs and 6 cohort studies, were selected for inclusion. Virologic suppression was reported in 14 studies with 12,457 individuals in TSIs and 23,592 receiving the standard of care. Optimal ART adherence was reported in 7 RCTs only (2,185 individuals in TSI and 1,545 receiving SOC). Optimal ART adherence was 7.6% higher in TSIs compared with SOC (pooled RR 1.076, 95% CI 1.005–1.151, p = 0.035). Heterogeneity of these studies was high (I2 = 91.1%). Virologic suppression was 5% higher in TSIs compared with the standard of care (pooled RR 1.05, 95% CI 1.019–1.081, P = 0.001). Meta-regression demonstrated that virologic suppression did not significantly vary by study type (b = −0.042, 95% CI −0.09–0.001, P = 0.057) and patient selection of the treatment supporter (b = 0.026, 95% CI −0.07–0.12, P = 0.554). Conclusion Optimal ART adherence is marginally higher in treatment supporter interventions compared with the standard of care. Patient-nominated supporters achieve similar rates of virologic suppression to facility-selected supporters, and could play a critical role in addressing disparities in health outcomes among PLWH. Disclosures All authors: No reported disclosures.

scholarly journals Tea Flavonoids and Risk of Cardiovascular and All-Cause Mortality: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Ding Ding Wang ◽  
Aedin Cassidy ◽  
Mario G. Ferruzzi ◽  
Paul Jacques ◽  
Elizabeth Johnson ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Green Tea ◽  
Lower Risk ◽  
Meta Analysis ◽  
Black Tea ◽  
Tea Consumption ◽  
Prospective Cohort Studies ◽  
All Cause Mortality ◽  
Meta Regression

AbstractThere is increasing evidence that both black and green tea are beneficial for prevention of cardiovascular disease (CVD). We conducted a systematic review and meta-analysis evaluating the effects of tea flavonoids on cardiovascular (CVD) and all-cause mortality outcomes.Searches across five databases including PubMed and Embase were conducted through November 2018 to identify randomized controlled trials (RCTs) and prospective cohort studies reporting cardiovascular and all-cause mortality outcomes. Two investigators independently conducted abstract and full-text screenings, data extractions, and risk of bias (ROB) assessments using the Nutrition Evidence Library Bias Assessment Tool (NEL BAT). Mixed-effects dose-response meta-regression and standard random-effects meta-analyses for outcomes with ≥ 4 studies were performed. 0 RCTs and 38 prospective cohort studies were included in the systematic review. NEL BAT scores ranged from 0–15 (0 being the lowest risk). Our linear meta-regression model showed that each cup increase in daily tea consumption (about 280 mg and 338 mg of total flavonoids for black and green tea, respectively) was associated with 3–4% lower risk of CVD mortality (predicted adjusted RR = 0.96; CI 0.93–0.99 for green tea and RR = 0.97; CI 0.94–0.99 for black tea). Furthermore, eachcup increase in daily tea consumption was associated a 2% lower risk of all-cause mortality (predicted adjusted relative risk (RR) = 0.98; 95% CI 0.97–0.99 for black tea and RR = 0.98; CI 0.96–0.99 for green tea, respectively). Two studies reported multivariable Cox regression analysis results for the relationship between black tea intake and risks of all-cause mortality outcomes. The results from these two studies were combined with our linear meta-regression result in a random-effects model meta-analysis and showed that each cup increase in daily black tea consumption was associated with an average of 3% lower risk of all-cause mortality (pooled adjusted RR = 0.97; 95% CI 0.87- 1.00) with large heterogeneity (I2 = 81.4%; p = 0.005). Current evidence indicates that increased tea consumption may reduce cardiovascular and all-cause mortality in a dose-response manner. This systematic review was registered on PROSPERO.

The relationship between endoscopic and clinical recurrence in postoperative Crohn’s disease: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Alessandro Ble ◽  
Cecilia Renzulli ◽  
Fabio Cenci ◽  
Maria Grimaldi ◽  
Michelangelo Barone ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Mixed Effects ◽  
Spearman Correlation ◽  
Clinical Recurrence ◽  
Endoscopic Recurrence ◽  
Meta Regression ◽  
The Relationship

Abstract Background and Aims We aimed to quantify the magnitude of the association between endoscopic recurrence and clinical recurrence [symptom relapse] in patients with postoperative Crohn’s disease. Methods Databases were searched to October 2, 2020 for randomised controlled trials [RCTs] and cohort studies of adult patients with Crohn’s disease with ileocolonic resection and anastomosis. Summary effect estimates for the association between clinical recurrence and endoscopic recurrence were quantified by risk ratios [RR] and 95% confidence intervals [95% CI]. Mixed-effects meta-regression evaluated the role of confounders. Spearman correlation coefficients were calculated to assess the relationship between these outcomes as endpoints in RCTs. An exploratory mixed-effects meta-regression model with the logit of the rate of clinical recurrence as the outcome and the rate of endoscopic recurrence as a predictor was also evaluated. Results Thirty-seven studies [N=4053] were included. For 8 RCTs with available data, the RR for clinical recurrence for patients who experienced endoscopic recurrence was 10.77 [95% CI 4.08-28.40; GRADE moderate certainty evidence]; the corresponding estimate from 11 cohort studies was 21.33 [95% CI 9.55-47.66; GRADE low certainty evidence]. A single cohort study showed a linear relationship between Rutgeerts score and clinical recurrence risk. There was a strong correlation between endoscopic recurrence and clinical recurrence treatment effect estimates as trial outcomes [weighted Spearman correlation coefficient 0.51]. Conclusions The associations between endoscopic recurrence and subsequent clinical recurrence lend support to the choice of endoscopic recurrence to monitor postoperative disease activity and as a primary endpoint in clinical trials of postoperative Crohn’s disease.

The Relationship Between Obesity and Lymphoma: A Meta-Analysis of Prospective Cohort Studies

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5198-5198 ◽  
Author(s):  
Randall R Ingham ◽  
John L. Reagan ◽  
Samir Dalia ◽  
Michael Furman ◽  
Basma Merhi ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Cohort Studies ◽  
Hodgkin Lymphoma ◽  
Prospective Cohort ◽  
Research Funding ◽  
Meta Analysis ◽  
Obese Patients ◽  
Prospective Cohort Studies ◽  
Increased Risk ◽  
Meta Regression

Abstract Abstract 5198 Introduction: Lymphoma is a common hematologic malignancy, etiology of which remains largely unclear. Obesity and overweight have been associated with an increased risk of developing lymphoma; however, with conflicting results. The main objective of this meta-analysis is to evaluate the potential relationship that overweight and obesity may have in the development of lymphoma in adults. A secondary objective was to evaluate the risk of separate lymphoma subtypes, such as Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) and the most common NHL subtypes – diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) – in overweight and obese individuals. Methods: A MEDLINE search from January 1950 to December 2010 was undertaken using: (obesity OR “body mass index” OR BMI OR overweight) AND (leukemia OR lymphoma OR myeloma). Only prospective cohort studies reporting on the incidence of lymphoma were included. Retrospective case-control and cross-sectional studies were excluded. Meta-analyses were performed for HL, NHL and NHL subtypes. The outcome was calculated as relative risk (RR). Overweight was defined as body mass index (BMI) 25–29.9 kg/m2 and obesity as BMI ≥30 kg/m2, according to the WHO criteria. The quality of the studies was determined by the Newcastle-Ottawa scale (NOS). The random effects model was used to calculate the combined outcome. Heterogeneity was assessed by the I2 statistic. Publication bias was assessed by the trim-and-fill analysis. Meta-regression analyses were performed to evaluate the association between BMI, as a continuous variable, and the incidence of HL and NHL in general and NHL subtypes. Literature search, data gathering and study quality assessment were performed independently by at least two of the investigators. All graphs and calculations were obtained using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ). Results: From 758 returns, 22 prospective cohort studies evaluating the association between obesity and lymphoma were identified. All the studies were of high quality (NOS >7 points). For NHL, the overall RR was 1.06 (95% CI 1.02–1.10; p=0.001). For overweight and obese patients, the RR were 1.04 (95% CI 1.01–1.07; p=0.02) and 1.11 (95% CI 1.06–1.16; p<0.001), respectively. Meta-regression showed a linear association between BMI and incidence of NHL (p<0.001). For DLBCL, the overall RR was 1.14 (95% CI 1.01–1.29; p=0.03). Overweight and obese patients had a RR of 1.08 (95% CI 0.96–1.22; p=0.22) and 1.24 (95% CI 1.08–1.44; p=0.003), respectively. Meta-regression showed a trend towards a significant association between BMI and incidence of DLBCL (p=0.1). For FL, the overall RR was 1.11 (95% CI 0.99–1.25; p=0.08). Overweight and obese patients had a RR of 1.10 (95% CI 0.94–1.28; p=0.25) and 1.15 (95% CI 0.97–1.36; p=0.11), respectively. Meta-regression showed no association between BMI and incidence of FL (p=0.78). For HL, the overall RR was 1.10 (95% CI 0.97–1.26; p=0.15). Overweight and obese patients had a RR of 0.91 (95% CI 0.80–1.03; p=0.13) and 1.23 (95% CI 1.05–1.44; p=0.009), respectively. Meta-regression showed a statistically significant linear relationship between BMI and incidence of HL (p=0.009). Conclusions: Obesity was associated with a mild increased risk of developing HL (23%), NHL in general (11%) and DLBCL (24%), but there was no association with FL. There was a statistically significant linear association between BMI and HL as well as for NHL in general, but only a trend towards an association with DLBCL. Disclosures: Castillo: GlaxoSmithKline: Research Funding; Millennium Pharmaceuticals: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document